Nutriband Inc
$ 4.80
1.27%
26 Dec - close price
- Market Cap 58,439,000 USD
- Current Price $ 4.80
- High / Low $ 4.91 / 4.64
- Stock P/E N/A
- Book Value 0.62
- EPS -3.05
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -1.36 %
- 52 Week High 11.78
- 52 Week Low 3.76
About
Nutriband Inc. is an innovative biotechnology company based in Orlando, Florida, specializing in the development of advanced transdermal drug delivery systems. Leveraging its proprietary technologies, Nutriband focuses on creating non-invasive pharmaceutical formulations that aim to enhance patient compliance and optimize therapeutic outcomes. With a robust commitment to research and development, the company is well-positioned to capitalize on the growing demand for alternative treatment solutions, reflecting strong potential for significant growth within the pharmaceutical industry.
Analyst Target Price
$15.00
Quarterly Earnings
| Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 | Apr 2023 | Jan 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-01 | 2025-10-01 | 2025-05-02 | 2025-04-28 | 2024-12-10 | 2024-09-03 | 2024-05-01 | 2024-04-30 | 2023-12-13 | 2023-09-11 | 2023-06-09 | 2023-04-26 |
| Reported EPS | -0.32 | -2.12 | -0.5 | -0.51 | -0.1227 | -0.1542 | -0.2072 | -0.2295 | -0.2247 | -0.1059 | -0.1296 | -0.21 |
| Estimated EPS | -0.19 | -0.17 | -0.12 | -0.12 | None | None | None | None | -0.06 | -0.07 | -0.06 | -0.04 |
| Surprise | -0.13 | -1.95 | -0.38 | -0.39 | 0 | 0 | 0 | 0 | -0.1647 | -0.0359 | -0.0696 | -0.17 |
| Surprise Percentage | -68.4211% | -1147.0588% | -316.6667% | -325% | None% | None% | None% | None% | -274.5% | -51.2857% | -116% | -425% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTRB
2025-12-27 00:16:00
This article discusses liquidity mapping for Nutriband Inc. (NASDAQ: NTRB) price events, featuring AI-generated institutional trading strategies. It outlines position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis indicating current price, resistance, and support levels. The analysis aims to help users optimize position sizing and minimize drawdown risk.
2025-12-20 08:09:50
Nutriband (NASDAQ: NTRB) has signed a nonbinding letter of intent with Qvanta Group of Companies to explore collaboration in secure artificial intelligence, advanced computing, and cybersecurity technologies. This initiative aims to support Nutriband’s research and long-term product development, focusing on secure AI platforms for pharmaceutical data, data integrity frameworks for abuse-deterrent technologies, and quantum-ready modeling and simulation. The LOI does not establish a commercial partnership but paves the way for potential future agreements.
2025-12-19 21:09:01
Nutriband (NASDAQ: NTRB) has signed a nonbinding letter of intent with Qvanta Group of Companies to explore collaboration in secure artificial intelligence, advanced computing, and cybersecurity. The discussions will focus on applying these technologies to Nutriband's pharmaceutical research and development, particularly for secure AI and analytics platforms for regulated data, data integrity for abuse-deterrent technologies, and quantum-ready modeling. This LOI does not establish a partnership but opens doors for future potential agreements.
2025-12-19 08:09:23
Nutriband Inc. has signed a non-binding Letter of Intent with Qvanta Group of Companies to explore collaboration on advanced technology solutions for abuse-deterrent pharmaceutical innovation. This strategic exploration aligns with federal priorities regarding the fentanyl crisis, artificial intelligence, and quantum technology, with Qvanta's quantum-AI capabilities potentially supporting Nutriband's research and product development initiatives for its AVERSA™ technology. The LOI focuses on areas like secure AI platforms for regulated pharmaceutical data, cybersecurity frameworks for abuse-deterrent technologies, and advanced modeling.
2025-12-19 01:09:28
Nutriband (NASDAQ: NTRB) has responded to the Trump Administration's Executive Order designating illicit fentanyl as a weapon of mass destruction, clarifying that this does not apply to FDA-approved prescription fentanyl therapies. The company highlighted its AVERSA™ FENTANYL development, a partnership with Kindeva, which aims to create an abuse-deterrent transdermal fentanyl patch. This technology seeks to prevent abuse, misuse, diversion, and accidental exposure while ensuring continued access for patients in need.
2025-12-18 14:10:00
Nutriband Inc. signed a non-binding Letter of Intent with Qvanta Group to explore collaborations in quantum-AI technologies for pharmaceutical data, cybersecurity, and advanced modeling. This initiative aligns with federal priorities regarding the fentanyl crisis, especially after its designation as a Weapon of Mass Destruction, as Nutriband develops abuse-deterrent fentanyl transdermal systems. The LOI does not establish a binding commercial relationship but positions Nutriband to leverage AI in addressing national security and pharmaceutical challenges.
